Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
or

Zynerba Pharma CS (ZYNE)

Zynerba Pharma CS (ZYNE)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
1.3000 +0.0300 (+2.36%) 10/10/23 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 1.3000 unch (unch) -
Quote Overview for Tue, Oct 10th, 2023
Day Low
1.2600
Day High
1.3400
Open 1.2600
Previous Close 1.2700 1.2700
Volume 862,700 862,700
Avg Vol 1,093,995 1,093,995
Stochastic %K 54.34% 54.34%
Weighted Alpha -35.90 -35.90
5-Day Change +0.0400 (+3.17%) +0.0400 (+3.17%)
52-Week Range 0.2500 - 1.4000 0.2500 - 1.4000
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 70,121
  • Shares Outstanding, K 53,939
  • Annual Sales, $ 0 K
  • Annual Income, $ -35,040 K
  • EBIT $ -39 M
  • EBITDA $ -39 M
  • 60-Month Beta 1.32
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.40
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.80
  • Most Recent Earnings $-0.21 on 08/14/23
  • Next Earnings Date 11/13/23
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Generic Drugs

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/23
See More
  • Average Estimate -0.20
  • Number of Estimates 2
  • High Estimate -0.19
  • Low Estimate -0.20
  • Prior Year -0.20
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1850 +9.70%
on 10/04/23
Period Open: 1.3200
1.4000 -7.14%
on 09/15/23
-0.0200 (-1.52%)
since 09/08/23
3-Month
0.2500 +420.00%
on 07/11/23
Period Open: 0.3302
1.4000 -7.14%
on 09/15/23
+0.9698 (+293.70%)
since 07/10/23
52-Week
0.2500 +420.00%
on 07/11/23
Period Open: 0.6998
1.4000 -7.14%
on 09/15/23
+0.6002 (+85.77%)
since 10/10/22

Most Recent Stories

More News
Why Shares of Harmony Bioscience Are Falling on Friday

The company reported underwhelming phase 3 trial results for Pitolisant to treat idiopathic hypersomnia.

ZYNE : 1.3000 (+2.36%)
HRMY : 29.26 (-5.52%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CPRI, CEQP, CELL, ZYNE

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

CPRI : 14.52 (-3.14%)
CEQP : 28.26 (+4.36%)
CELL : 0.9981 (+0.31%)
ZYNE : 1.3000 (+2.36%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVID, ZYNE, HEP, CEQP

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

AVID : 27.04 (unch)
ZYNE : 1.3000 (+2.36%)
HEP : 20.45 (-0.78%)
CEQP : 28.26 (+4.36%)
Shareholder Alert: Ademi LLP investigates whether Zynerba Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Harmony

/PRNewswire/ -- Ademi LLP is investigating Zynerba (Nasdaq: ZYNE) for possible breaches of fiduciary duty and other violations of law in its transaction with...

ZYNE : 1.3000 (+2.36%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CPRI, AVID, ZYNE, HEP

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

CPRI : 14.52 (-3.14%)
AVID : 27.04 (unch)
ZYNE : 1.3000 (+2.36%)
HEP : 20.45 (-0.78%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TRHC, DBTX, VRTV, ZYNE

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

TRHC : 10.50 (+0.86%)
DBTX : 4.91 (-0.81%)
VRTV : 169.99 (+0.02%)
ZYNE : 1.3000 (+2.36%)
Zynerba: Q2 Earnings Snapshot

Zynerba: Q2 Earnings Snapshot

ZYNE : 1.3000 (+2.36%)
HARMONY BIOSCIENCES TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC.

/PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative...

HRMY : 29.26 (-5.52%)
ZYNE : 1.3000 (+2.36%)
Zynerba: Q1 Earnings Snapshot

Zynerba: Q1 Earnings Snapshot

ZYNE : 1.3000 (+2.36%)
Zynerba: Q4 Earnings Snapshot

Zynerba: Q4 Earnings Snapshot

ZYNE : 1.3000 (+2.36%)

Business Summary

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal...

See More

Key Turning Points

3rd Resistance Point 1.4200
2nd Resistance Point 1.3800
1st Resistance Point 1.3400
Last Price 1.3000
1st Support Level 1.2600
2nd Support Level 1.2200
3rd Support Level 1.1800

See More

52-Week High 1.4000
Last Price 1.3000
Fibonacci 61.8% 0.9607
Fibonacci 50% 0.8250
Fibonacci 38.2% 0.6893
52-Week Low 0.2500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades